These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36734271)

  • 1. AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells.
    Harata S; Suzuki T; Takahashi H; Hirokawa T; Kato A; Watanabe K; Yanagita T; Ushigome H; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takiguchi S
    Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36734271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by inhibiting repair of DNA damage.
    Suzuki T; Hirokawa T; Maeda A; Harata S; Watanabe K; Yanagita T; Ushigome H; Nakai N; Maeda Y; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takahashi H; Takiguchi S
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35191521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
    Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    PLoS One; 2022; 17(4):e0266476. PubMed ID: 35413091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
    Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
    Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer.
    Nukatsuka M; Fujioka A; Nagase H; Tanaka G; Hayashi H
    Chemotherapy; 2023; 68(2):102-110. PubMed ID: 36623495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
    Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
    Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
    Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks.
    Matsuoka K; Iimori M; Niimi S; Tsukihara H; Watanabe S; Kiyonari S; Kiniwa M; Ando K; Tokunaga E; Saeki H; Oki E; Maehara Y; Kitao H
    Mol Cancer Ther; 2015 Apr; 14(4):1004-13. PubMed ID: 25700705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Biskup E; Naym DG; Gniadecki R
    J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ataxia telangiectasia and Rad3-related (ATR) inhibition by VE-822 potently reversed 5-flourouracil resistance in colorectal cancer cells through targeting DNA damage response.
    Mihanfar A; Asghari F; Majidinia M
    Mol Biol Rep; 2024 Mar; 51(1):474. PubMed ID: 38553623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
    Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway.
    Chaudhary P; Sharma R; Sahu M; Vishwanatha JK; Awasthi S; Awasthi YC
    J Biol Chem; 2013 Jul; 288(28):20532-46. PubMed ID: 23733185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATF2 loss promotes 5-FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway.
    Yang H; Huebner K; Hampel C; Erlenbach-Wuensch K; Selvamani SB; Shukla V; Geppert CI; Hartmann A; Mahadevan V; Schneider-Stock R
    BMC Cancer; 2023 May; 23(1):480. PubMed ID: 37237279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment-Resistant Cancer Cells.
    Barnieh FM; Morais GR; Loadman PM; Falconer RA; El-Khamisy SF
    Adv Sci (Weinh); 2024 Sep; 11(34):e2403831. PubMed ID: 38976561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved chemoradiation treatment using trifluridine in human colorectal cancer cells in vitro.
    Matsuoka K; Kobunai T; Nukatsuka M; Takechi T
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):249-255. PubMed ID: 29024630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy.
    Iwata T; Uchino T; Koyama A; Johmura Y; Koyama K; Saito T; Ishiguro S; Arikawa T; Komatsu S; Miyachi M; Sano T; Nakanishi M; Shimada M
    PLoS One; 2017; 12(5):e0178221. PubMed ID: 28558031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.